Morris J, Milledge J S, Moszoro H, Higgins A
Br J Dis Chest. 1984 Oct;78(4):383-7.
The efficacy of terbutaline delivered via a 750 ml spacer device (Nebuhaler) compared with a metered dose inhaler alone was studied by means of an open cross-over trial in eight patients with stable asthma. The FEV1 and FVC response curves with cumulative doses up to 8 mg were shifted significantly to the left using the device, whilst side effects were not significantly increased. These results indicate that the spacer significantly improves aerosol drug delivery from a pressurized inhaler, even in patients whose inhalation technique was considered adequate.
通过一项开放性交叉试验，在8名稳定期哮喘患者中研究了使用750毫升储雾罐装置（百瑞雾化吸入器）与单独使用定量气雾剂相比，特布他林的疗效。使用该装置时，累积剂量高达8毫克的FEV1和FVC反应曲线显著左移，而副作用没有显著增加。这些结果表明，即使在吸入技术被认为合格的患者中，储雾罐也能显著改善来自压力定量吸入器的气雾剂药物递送。
